VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com initiated coverage on shares of VolitionRx (NYSE:VNRX) in a research note published on Thursday morning. The firm issued a sell rating on the stock.

VNRX has been the subject of a number of other research reports. D. Boral Capital reaffirmed a “buy” rating and issued a $5.00 price objective on shares of VolitionRx in a research note on Wednesday, January 8th. Benchmark reaffirmed a “hold” rating on shares of VolitionRx in a report on Friday, November 22nd.

VolitionRx Price Performance

NYSE VNRX opened at $0.62 on Thursday. The business’s 50-day moving average is $0.64 and its 200 day moving average is $0.66. VolitionRx has a 1 year low of $0.43 and a 1 year high of $1.23. The stock has a market capitalization of $57.91 million, a PE ratio of -1.74 and a beta of 1.20.

Insider Buying and Selling

In other VolitionRx news, CEO Cameron John Reynolds bought 139,811 shares of the company’s stock in a transaction on Monday, December 9th. The shares were bought at an average cost of $0.57 per share, for a total transaction of $79,692.27. Following the acquisition, the chief executive officer now directly owns 2,117,404 shares in the company, valued at approximately $1,206,920.28. The trade was a 7.07 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Guy Archibald Innes purchased 174,764 shares of the stock in a transaction dated Monday, December 9th. The stock was acquired at an average cost of $0.57 per share, with a total value of $99,615.48. Following the transaction, the director now directly owns 617,085 shares in the company, valued at approximately $351,738.45. This trade represents a 39.51 % increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 358,266 shares of company stock valued at $204,212 over the last quarter. 12.80% of the stock is owned by corporate insiders.

Institutional Trading of VolitionRx

An institutional investor recently raised its position in VolitionRx stock. Ground Swell Capital LLC boosted its position in shares of VolitionRx Limited (NYSE:VNRX) by 78.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 45,959 shares of the company’s stock after acquiring an additional 20,249 shares during the period. Ground Swell Capital LLC’s holdings in VolitionRx were worth $28,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 8.09% of the company’s stock.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.